Investment Ratings
-
Master Rating:
-
Suven Life Sciences has an operating revenue of Rs. 6.26 Cr. on a trailing 12-month basis. An annual revenue de-growth of -25% needs improvement, Pre-tax margin of -575% needs improvement, ROE of -66% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 2 which is a POOR score indicating inconsistency in earnings, a RS Rating of 31 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 147 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.
EPS Strength
Price Strength
Buyer Demand
Group Rank
Analyst Recommendation : HOLD
Suven Life Sciences Ltd Forecast
Price Estimates
Eps And Sales Estimates
Suven Life Sciences Ltd Synopsis
NSE-Medical-Diversified
Suven Life Sciences is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 13.48 Cr. and Equity Capital is Rs. 12.73 Cr. for the Year ended 31/03/2021. Suven Life Sciences Ltd. is a Public Limited Listed company incorporated on 09/03/1989 and has its registered office in the State of Andhra Pradesh, India. Company’s Corporate Identification Number(CIN) is L24110TG1989PLC009713 and registration number is 009713.-
Market Cap
INR 1,174.19 Cr
-
Sales
INR 6.26 Cr
-
Shares in Float
5.09 Cr
-
No of Funds
15 K
-
Yield
0.89%
-
Book Value
2.84
-
U/D Vol Ratio
2
-
LTDebt/Equity
0%
-
Alpha
-0.02
-
Beta
1.2
| Owner Name | Jun-21 | Mar-21 | Dec-20 |
|---|---|---|---|
| Promoters | 60% | 60% | 60% |
| Mutual Funds | 0.01% | 0.21% | 0.25% |
| Foreign Portfolio Investors | 0.41% | 0.48% | 1.05% |
| Financial Institutions/ Banks | 0% | 0% | 0% |
| Individual Investors | 34.22% | 33.92% | 32.07% |
| Others | 5.36% | 5.39% | 6.63% |
| Name | Designation |
|---|---|
| Mr. Venkateswarlu Jasti | Chairman & CEO |
| Mrs. Sudharani Jasti | Whole Time Director |
| Mrs. J A S Padmaja | Director |
| Prof. Seyed E Hasnain | Director |
| Mr. M Gopalakrishna | Director |
| Mr. Santanu Mukherjee | Director |
Suven Life Sciences Ltd Financials
- Quarterly P&L
- Annual P&L
- Cash Flow
- Balance Sheet
- Ratios
| INDICATOR | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 |
|---|---|---|---|---|---|
| Oper Rev Qtr Cr | 1.1841 | 2.0061 | 1.5571 | 1.513 | 8.9796 |
| Operating Expenses Qtr Cr | 11.4855 | 13.867 | 10.0348 | 11.8829 | 12.8233 |
| Operating Profit Qtr Cr | -10.3014 | -11.8609 | -8.4777 | -10.3699 | -3.8437 |
| Depreciation Qtr Cr | 1.0343 | 1.0343 | 1.0656 | 1.1411 | 1.0746 |
| Interest Qtr Cr | 0.1499 | 0.1529 | 0.2419 | 0.167 | 0.2532 |
| Tax Qtr Cr | 0 | 0 | 0.0458 | -1.9068 | -0.9946 |
| Net Profit Qtr Cr | -10.9828 | -8.4929 | -8.5079 | -8.1471 | -1.8997 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Total Revenue Annual Cr | 21.232 | 28.451 | 312.9147 | 648.5291 | 564.6242 |
| Operating Expenses Annual Cr | 44.0253 | 49.6781 | 236.9686 | 392.3424 | 378.1884 |
| Operating Profit Annual in Cr | -30.547 | -35.2634 | 48.7011 | 232.916 | 165.3433 |
| Depreciation Cr | 4.3462 | 4.1687 | 10.7897 | 21.3099 | 21.4131 |
| Interest Annual Cr | 0.8154 | 0.5403 | 1.9026 | 4.6111 | 5.6658 |
| Tax Annual Cr | -5.3228 | -12.1829 | 24.0601 | 71.8384 | 35.8832 |
| Net Profit Annual Cr | -22.6321 | -13.7532 | 39.1937 | 158.4273 | 123.4737 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Cash from Operating Activity Annual Cr | -36.6849 | -103.428 | -12.0121 | 104.7712 | 147.2748 |
| Cash from Investing Activity Annual Cr | 2.4123 | 101.37 | 3.1983 | -37.8058 | -352.6125 |
| Cash from Financing Annual Activity Cr | 34.8557 | 2.7529 | 4.5454 | -52.0491 | -30.37 |
| Net Cash Flow Annual Cr | 0.5831 | 0.6949 | -4.2684 | 14.9163 | -235.7077 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Total ShareHolders Funds Annual Cr | 401.6545 | 387.6735 | 401.7221 | 866.6998 | 731.5292 |
| Fixed Assets Annual Cr | 25.7366 | 24.6937 | 22.3683 | 332.4694 | 315.4404 |
| Total Non Current Assets Annual Cr | 320.7621 | 357.7593 | 158.7316 | 451.8131 | 388.982 |
| Total Current Assets Annual Cr | 94.6239 | 51.9976 | 280.7555 | 562.6633 | 487.1875 |
| Total Assets Annual Cr | 415.386 | 409.7569 | 439.4871 | 1014.4764 | 876.1695 |
| INDICATOR | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|
| Book Value Per Share Annual Rs | 31.5562 | 30.4578 | 31.5615 | 68.0928 | 57.4731 |
| ROE Annual % | -5.63 | -3.54 | 9.75 | 18.27 | 16.87 |
| ROCE Annual % | -6.68 | -6.35 | 15.28 | 26.18 | 21.66 |
| Total Debt to Total Equity Annual | - | - | - | - | - |
| EBDIT Annual Margin % | -169.11 | -147.26 | 26.58 | 40.97 | 34.3 |
Suven Life Sciences Ltd Technicals
EMA & SMA
CURRENT PRICE
92 
(2.62)
-
- Bullish Moving Averages 7
- Bearish Moving Averages 9
EMA
-
20 Day
93.63
-
50 Day
95.95
-
100 Day
94.61
-
200 Day
91.17
Suven Life Sciences Ltd Resistance and support
90.09 PIVOT
-
First Resistance
90.97
-
Second Resistance
92.29
-
Third Resistance
93.17
-
First Support
88.77
-
Second Support
87.89
-
Third Support
86.57
-
RSI
44.91
-
MFI
42.51
-
MACD
-2.88
-
MACD signal line
-2.79
Suven Life Sciences Ltd Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 301,582 | 12,307,561 | 40.81% |
| Week | 205,892 | 10,051,657 | 48.82% |
| 1 Month | 350,096 | 16,307,465 | 46.58% |
| 6 Month | 899,733 | 38,445,585 | 42.73% |
Suven Life Sciences Ltd Price change analysis
-8.95
Over 1 month
Low High 86.5 104.9
7.8
Over 3 month
Low High 81.6 124.45
-6.7
Over 6 months
Low High 73 124.45
18.25
Over Year
Low High 67.75 124.45Similar Stocks
| Company Name | 52 Week () |
Market Price () | Volume |
|---|---|---|---|
| Bliss GVS Pharma Ltd | 224.00 | 101.20 (0.55%) | 15376 |
| Alembic Pharmaceuticals Ltd | 1,150.00 | 813.05 (2.73%) | 56336 |
| Vineet Laboratories Ltd | 124.70 | 69.90 (-0.14%) | 5921 |
| Panacea Biotec Ltd | 453.70 | 202.75 (0.70%) | 9516 |
News
Suven Life Sci Consolidated September 2021 Net Sales at Rs 1
NULL Read More
Suven Life Sciences Ltd - 530239 - Announcement under Regula
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed t Read More
SUVEN LIFE SCIENCES LTD. - 530239 - Statement Of Deviation(S
With reference to the above subject, please find enclosed statement confirming that there were no deviation(s) or variation(s) in the use of Read More
Q2FY22 Result Quarterly Announced for Suven Life Sciences Lt
Highlights Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous Read More
SUVEN LIFE SCIENCES LTD. - 530239 - Un-Audited Standalone An
We are enclosing herewith the following documents: a) Un-audited Standalone and Consolidated Financial Results under Ind AS for the quarter Read MoreBlogs